6161. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
作者: Sara Y Tartof.;Jeff M Slezak.;Heidi Fischer.;Vennis Hong.;Bradley K Ackerson.;Omesh N Ranasinghe.;Timothy B Frankland.;Oluwaseye A Ogun.;Joann M Zamparo.;Sharon Gray.;Srinivas R Valluri.;Kaije Pan.;Frederick J Angulo.;Luis Jodar.;John M McLaughlin.
来源: Lancet. 2021年398卷10309期1407-1416页
Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer-BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system.
6164. Fatal police violence by race and state in the USA, 1980-2019: a network meta-regression.
The burden of fatal police violence is an urgent public health crisis in the USA. Mounting evidence shows that deaths at the hands of the police disproportionately impact people of certain races and ethnicities, pointing to systemic racism in policing. Recent high-profile killings by police in the USA have prompted calls for more extensive and public data reporting on police violence. This study examines the presence and extent of under-reporting of police violence in US Government-run vital registration data, offers a method for correcting under-reporting in these datasets, and presents revised estimates of deaths due to police violence in the USA.
6175. Hypertrophic cardiomyopathy: a practical approach to guideline directed management.
Hypertrophic cardiomyopathy, one of the most common genetic cardiovascular conditions, will be encountered by nearly every health-care provider regardless of specialty. In 2020, new hypertrophic cardiomyopathy management guidelines were published, updating and evolving preceding versions. This Seminar provides a concise review and practical guide to the updated recommendations for patients with hypertrophic cardiomyopathy.
6177. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation.
作者: Ildiko Lingvay.;Priya Sumithran.;Ricardo V Cohen.;Carel W le Roux.
来源: Lancet. 2022年399卷10322期394-405页
Obesity is now recognised as a disease that is associated with serious morbidity and increased mortality. One of its main metabolic complications is type 2 diabetes, as the two conditions share key pathophysiological mechanisms. Weight loss is known to reverse the underlying metabolic abnormalities of type 2 diabetes and, as such, improve glucose control; loss of 15% or more of bodyweight can have a disease-modifying effect in people with type 2 diabetes, an outcome that is not attainable by any other glucose-lowering intervention. Furthermore, weight loss in this population exerts benefits that extend beyond glycaemic control to improve risk factors for cardiometabolic disease and quality of life. We review the evidence supporting the role of weight loss in the management of type 2 diabetes and propose that many patients with type 2 diabetes would benefit from having a primary weight-centric approach to diabetes treatment. We discuss the logistical challenges to implementing a new weight-centric primary treatment goal in people with type 2 diabetes.
6178. Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry.
作者: Ryan P Barbaro.;Graeme MacLaren.;Philip S Boonstra.;Alain Combes.;Cara Agerstrand.;Gail Annich.;Rodrigo Diaz.;Eddy Fan.;Katarzyna Hryniewicz.;Roberto Lorusso.;Matthew L Paden.;Christine M Stead.;Justyna Swol.;Theodore J Iwashyna.;Arthur S Slutsky.;Daniel Brodie.; .
来源: Lancet. 2021年398卷10307期1230-1238页
Over the course of the COVID-19 pandemic, the care of patients with COVID-19 has changed and the use of extracorporeal membrane oxygenation (ECMO) has increased. We aimed to examine patient selection, treatments, outcomes, and ECMO centre characteristics over the course of the pandemic to date.
|